Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 15;221(12):e20240959. doi: 10.1084/jem.20240959

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Li et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — MCRS1 sensitizes α-PD-1 immunotherapy in mice and humans. (A) The tumor growth curve of control and Mcrs1^OX tumors treated with an α-PD-1 antibody (n = 7 for all groups; presented as means ± SEM; ns, not significant, P ≥ 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-way ANOVA with Sidak’s multiple comparisons test; N = 2 independent experiments). Illustration was created with https://BioRender.com. (B) Spider plots showing tumor growth in individual mice as in A. (C) Tumor weights at the point of sacrifice (n = 7 for all groups; presented as means ± SEM; ns, not significant, P ≥ 0.05; *, P < 0.05; two-way ANOVA with Sidak’s multiple comparisons test; N = 2 independent experiments). (D) Tumor responses to NAC of PDAC patients with different MCRS1 levels, determined by histological evaluation (n = 40, 27 for MCRS1-low and MCRS1-high groups, respectively; ****, P < 0.0001; Chi-square test). (E) Overall survival (OS) of PDAC patients with different MCRS1 levels after NAC treatment (n = 40, 27 for MCRS1-low and MCRS1-high groups, respectively; Kaplan–Meier test). (F) Progression-free survival (PFS) of PDAC patients with different MCRS1 levels after NAC treatment (n = 40, 27 for MCRS1-low and MCRS1-high groups, respectively; Kaplan–Meier test). (G) Correlation between MCRS1 and MHC-I (HLA-A,B,C) expression in TCGA cancer types. (H) Representative IHC images showing high and low expression of MCRS1 (brown) in clinical samples of human NSCLC patients. Scale bars in the left panels = 100 μm; scale bars in the right panels = 20 μm. (I) Overall survival of NSCLC patients with different MCRS1 levels after α-PD-1 treatment (n = 60, 48 for MCRS1-low and MCRS1-high groups, respectively; Kaplan–Meier test). (J) Progression-free survival of NSCLC patients with different MCRS1 levels after α-PD-1 treatment (n = 65, 59 for MCRS1-low and MCRS1-high groups, respectively; Kaplan–Meier test). (K) Representative images showing MCRS1 levels in paired biopsies before and after α-PD-1 treatment (n = 25 for both groups). Scale bars = 50 μm. (L) MCRS1 expression in paired biopsies from the same patients before and after α-PD-1 treatment (n = 25 for both groups; *, P < 0.05; two-tailed paired t test).